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Background: Targeted therapies in renal cell carcinoma can have different effects on primary and metastatic
tumors. To pave the way for predictive biomarker development, we assessed differences in expression of targets of
currently approved drugs in matched primary and metastatic specimens from 34 patients.
Methods: Four cores from each site were embedded in tissue microarray blocks. Expression of B-Raf, C-Raf, cKIT,
FGF-R1, HIF-2α, mTOR, PDGF-Rβ, VEGF-R1, VEGF-R2, VEGF-R3, VEGF, VEGF-B, VEGF-C, VEGF-D, MEK1, and ERK1/2 was
studied using a quantitative immunofluorescence method.
Results: No significant differences were observed in global expression levels in primary and metastatic renal cell
carcinoma tumors, with the exception of MEK, which had higher expression in metastatic than primary specimens.
Similarly, more ki67 positive cells were seen in metastatic specimens. Correlations between marker expression in
primary and metastatic specimens were variable, with the lowest correlation seen for FGF-R1 and VEGF-D. There
were no significant differences in the degree of heterogeneity in primary versus metastatic tumors.
Conclusions: Expression of most of the studied markers was similar in primary and metastatic renal cell carcinoma
tumors, suggesting that predictive biomarker testing for these markers can be conducted on either the primary or
metastatic tumors for most markers.
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In recent years, the incidence of renal cell carcinoma
(RCC) has increased from 38,000 new cases a year in
2006 to over 64,000 estimated for 2012 [1,2]. This
increase is largely due to incidental radiographic identi-
fication of renal masses; within this expanding popula-
tion, RCC diagnoses are shifting towards earlier stage,
smaller tumors [3,4]. Despite early detection, the RCC
mortality rate remains fairly stable at 13,570 estimated
annual deaths [2]. The five-year survival rates for
patients with organ-confined disease is >85%, and >50%
for patients with regional spread [5], suggesting that
tumor biology is variable within the different disease
stages.* Correspondence: harriet.kluger@yale.edu
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reproduction in any medium, provided the orSurgery followed by surveillance imaging is the stand-
ard of care for RCC patients with localized disease. Fine
needle aspiration or core needle biopsies are commonly
employed for diagnosis of metastatic disease in the 10-
50% of these patients with recurring disease. More than
20% of RCC patients present with metastatic disease
without having a previously known localized primary
tumor [6,7].
RCC is very resistant to standard chemotherapy. Des-
pite advances in biological and immune-based therapies,
treatment options for patients with unresectable or
metastatic RCC (mRCC) are limited; response rates
remain at about 15–44%, and five-year survival under
10% for those with distant metastases [6,8-10]. Im-
munotherapy once represented the standard treatment
for mRCC; interferon-alpha (IFN-α) produces objective
responses in 10-15% of patients with a median survival
of 12 months, while high-dose Interleukin-2 (IL-2)
induces durable remissions in approximately 10% of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toxicity [12]. Alternative approaches have thus been
developed in recent years.
A growing understanding of the pathogenesis of clear
cell RCC, the most common histologic subtype, has
facilitated development of RCC-targeting therapies.
The discovery of Von Hippel-Lindau (VHL) tumor-
suppressor gene inactivation and subsequent hypoxia-
induced factor (HIF) activation of genes and downstream
pathways important to tumor progression have provided
the impetus for development of new agents that target
angiogenesis and proliferation pathways. A number of
drugs that target the vascular endothelial growth factor
(VEGF) pathway and downstream signaling molecules
have been approved for mRCC. These include the small
molecule tyrosine kinase inhibitors (TKIs) sunitinib,
sorafenib, pazopanib, and axitinb [10,13-15], the anti-
VEGF antibody bevacizumab [16-18], and the mTOR
inhibitors temsirolimus and everolimus [19,20]. Other
histologic subtypes have different underlying molecular
abnormalities, although responses to VEGF and mTOR
targeting therapies have been seen in subsets of non-
clear cell tumors as well. Although these new agents
improve progression free survival and, in some cases,
overall survival, none are curative and duration of
response is often limited.
Response of primary RCC (as opposed to metastatic
deposits) to targeted therapies has not been well stud-
ied, however highly sensitive cases are thought to be
relatively uncommon. Several groups have reported that
pre-surgical targeted therapy can be effective in mRCC
patients who have not had their primary tumors
removed [21-24]. However, a recent comprehensive
study showed minimal to no decrease in the primary
tumor diameter in mRCC patients. Patients with a >10%
reduction in size of their primary tumors are 2.25 times
more likely to have a partial response or stable disease
with systemic therapy, indicating that there can be
discordance in tumor shrinkage between primary and
metastatic tumors in mRCC patients who have not had
a nephrectomy [25]. Ongoing clinical trials are assessing
the benefits of targeted therapy prior to cytoreductive
nephrectomy (NCT00930033, NCT01099423).
At present no predictive biomarkers have been devel-
oped to identify patients whose tumors are more likely
to respond to any of the currently available therapies. In
addition, biomarkers predictive of discordant response
between primary and metastatic tumors are lacking. It is
therefore necessary to establish patterns of expression
of drug targets in tumors in order to attempt to develop
predictive tissue based biomarker assays. Given that
these drugs exert their effects on the proteome, protein-
level predictive biomarkers are a logical place to start.
Patterns of expression of drug targets in primary andmetastatic RCC tumors have not been previously well
demonstrated. Youssif et al. studied 25 matched primary
and metastatic samples for correlations between mTOR
pathway targets (PTEN, PI3K, p-Akt, phospho-mTOR
and p70S6) and found a strong correlation for phospho-
mTOR [26]. Here we assess levels of a number of pro-
teins, focusing on targets of currently approved drugs,
in four cores from primary tumors and corresponding
metastatic deposits. Given the limitations of immuno-
histochemistry in terms of subjectivity and qualitative
assessment of protein expression, we employed a
method of quantitative immunofluorescence to measure
protein levels. We found that while levels of most mar-
kers were not significantly different between primary
and metastatic tumors, some markers showed less
concordance.
Methods
Cohort details and tissue microarray (TMA) construction
Thirty-four patients with archived matched primary and
metastatic RCC tumors were identified. Resections were
done between 1972 and 2011. TMAs were constructed
using cores measuring 0.6 mm in diameter, spaced
0.8 mm apart. Tumors from each of the primary and
metastatic tumors were represented by four cores from
different areas of the specimen (eight cores in total from
each patient) and placed in two TMA blocks. Specimens
and clinical information were collected with approval of
a Yale University Institutional Review Board.
Immunofluorescence
Pairs of slides (containing two cores from different
areas of each matching primary and metastatic tumor
per patient) were stained individually for the target
markers; B-Raf, C-Raf, cKIT, FGF-R1 (fibroblast growth
factor receptor-1), HIF-2α (hypoxia induced factor-2α),
mTOR (mammalian target of rapamycin), PDGF-Rβ
(platelet-derived growth factor receptor-β), VEGF-R1,
VEGF-R2, VEGF-R3, VEGF, VEGF-B, VEGF-C, VEGF-D,
MEK1 (mitogen activated protein kinase-1), and ERK1/
2 (extracellular signal related kinase 1/2). TMAs were
also stained for ki67 as a marker of proliferation. Fluores-
cent staining for our Automated, Quantitative Analysis
(AQUA) method was performed as previously described
[27,28]. Briefly, slides were incubated with mouse
monoclonal anti-human VEGF-D (R&D Systems,
Minneapolis, MN, USA), FGF-R1 (QED Bioscience, San
Diego, CA, USA), HIF-2α (Novus Biologicals, Littleton,
CO, USA), ERK1/2 (Cell Signaling Technologies,
Danvers, MA, USA), PDGF-Rβ (Cell Signaling Tech-
nologies, Danvers, MA, USA), ki67 (BD Biosciences,
San Jose, California, USA), rabbit monoclonal anti-
human C-Raf(Upstate/EMD Millipore, Billerica, MA,
USA) mTOR (Cell Signaling Technologies, Danvers,
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MA, USA) and rabbit polyclonal B-Raf, VEGF-R1, VEGF-
R2, VEGF-R3 (Santa Cruz Biotechnologies, Santa Cruz,
CA, USA), c-Kit (DAKO, Carpinteria, CA, USA) VEGF,
VEGF-B (Santa Cruz Biotechnologies, Santa Cruz, CA,
USA), VEGF-C (Invitrogen, Carlsbad, CA, USA) overnight
at 4C. Goat anti-mouse (or anti-rabbit) HRP-decorated
polymer backbone (Envision, Dako, Carpinteria, CA,
USA) was used as a secondary reagent. Slides were incu-
bated with Cyanine5-tyramide (Perkin Elmer, Waltham,
MA) in the supplied amplification buffer for 10 min at
room temperature. Slides were incubated twice for
7 minutes with 100 mM benzoic hydrazide (B13071,
Sigma, St. Louis, MO) and 50 mM hydrogen peroxide in
PBS to quench the HRP. To create a tumor mask, slides
were incubated with a cocktail of rabbit (for VEGF-D,
FGF-R1, HIF-2α, ERK1/2, PDGF-Rβ, ki67) or mouse
(for B-Raf, C-Raf, VEGF-R1, VEGF-R2, VEGF-R3, c-Kit,
VEGF, VEGF-B, VEGF-C, mTOR and MEK1) anti-
cytokeratin (Dako, Carpinteria, CA, USA) 1:100 and
HRP-streptavidin(Sigma, St. Louis, MO, USA) for 1 hour
at room temperature. HRP-streptavidin binds endogenous
biotin which is present is high amounts in RCC and
renal tubules. Goat anti-mouse (or anti-rabbit) HRP-
decorated polymer backbone (Envision, Dako, Carpinteria,
CA, USA) was used as a secondary reagent. Slides were
incubated with Cyanine2-tyramide (Perkin Elmer,
Waltham, MA, USA) in the supplied amplification buf-
fer for 10 min at room temperature. To create a nuclear
mask, TMAs were incubated with 4, 6-diamidine-
2-phenylindole (DAPI) at a concentration of 1:500 in
0.3% BSA in TBS. Coverslips were mounted with Pro-
Long Gold antifade reagent with 4, 6-diamidine-
2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA).Automated image acquisition and analysis
Images were acquired and analyzed using previously
described algorithms [29]. Briefly, monochromatic,
high-resolution (1024 × 1024 pixel) images were
obtained of each histospot. Tumor was distinguished
from stroma by the cytokeratin/streptavidin signal. Cell
surface coalescence of cytokeratin was used to localize
membranes and DAPI to identify nuclei. The target
signal (B-Raf, C-Raf, cKIT, FGF-R1, HIF-2α, mTOR,
PDGF-Rβ, VEGF-R1, VEGF-R2, VEGF-R3, VEGF,
VEGF-B, VEGF-C, VEGF-D, MEK1, and ERK1/2) from
the pixels within the cytoplasm was normalized to area
of tumor mask and scored on a scale of 0–255 (the
AQUA score). Ki-67 positivity was calculated as a
percentage of tumor cells. Histospots were excluded if
the tumor mask represented <5% of the histospot area
or if there was anomalous staining (lacking DAPI or
cytokeratin, or necrotic tissue).Statistical analysis
Statview and JMP 5.0 software were used (SAS Institute,
Cary, NC). AQUA scores for replicate tumor cores were
averaged. Associations between continuous AQUA scores
of the target and clinical and pathological parameters were
assessed using ANOVA. Correlations between the AQUA
scores of matched primary and metastatic histospots
were calculated by the log rank method. Intratumor
heterogeneity was assessed by Pearson linear regression.
Results
Patient characteristics are summarized in Table 1.
Histological subtypes included clear cell (ccRCC)
(91.2%) and mixed histology (8.8%). Age at diagnosis
was 17–72 years (median-56). Performance status, LDH,
hemoglobin and calcium levels were not available.
Each lot of antibodies was subjected to immunoblot-
ting to verify presence of a single dominant band of the
appropriate size (not shown). We note that a number of
antibodies to VEGF-R2 are commercially available, and
a recent publication demonstrated higher specificity of the
55B11 antibody (Cell Signaling Technologies, Danvers,
MA) than the A-3 antibody (Santa Cruz Biotechnologies,
Inc, Santa Cruz, CA) [30]. However, in our hands, using
quantitative immunofluorescence, we found superior
correlations between redundant spots, membrane-
specific staining and better reproducibility of results
with the A-3 antibody. Western blotting for the A-3
antibody showed a single band at the associated protein
size. The discrepancy between our findings and those of
Molhoek et al. [30] might be due to batch-to-batch
variability and the quantitative staining method used
here. Information on antibodies used is given in the
Additional file 1: Table S1.
Figure 1a-d shows an example of C-Raf expression in
corresponding primary and metastatic tissues of one
patient. AQUA scores for the primary and metastatic
tumors for this patient were 66.28 and 64.14, respect-
ively. To assess intratumor heterogeneity, four distinct
cores from both the primary and metastatic sites were
used to evaluate expression of all the markers. Subse-
quently, scores from corresponding cores were averaged
to obtain a single concatenated score for each tumor for
each marker.
Global distribution of scores in primary and meta-
static spots was not significantly different for any of the
markers with the exception of MEK1. The mean AQUA
scores and the differences between primary and meta-
static tumors by paired t-tests are shown in Table 2. No
significant differences were found between expression
in primary and metastatic specimens for B-Raf, C-Raf,
cKIT, FGF-R1, HIF-2α, mTOR, PDGF-Rβ, VEGF-R1,
VEGF-R2, VEGF-R3, VEGF, VEGF-B, VEGF-C, VEGF-D,
and ERK1/2. Expression of MEK1 was somewhat higher
Table 1 Patient characteristics










1 6 51 5 Clear Cell 3 M Lung
2 72 64 3.2 Clear Cell 3 M Lung
3 6 50 10 Clear Cell 3 M Abdominal Wall
4 12 45 7 Clear Cell 3 M Skin
5 12 70 4 Clear Cell 2 M Lung
6 6 58 3 Clear Cell 2 F Colon
7 24 17 13 Clear Cell 3 F Lung
8 36 66 4 Clear Cell 2 M Lung
9 24 64 10.7 Clear Cell 3 M Liver
10 48 69 6 Clear Cell 3 F Skin
11 36 61 8 Clear Cell 3 F Lung
12 24 61 8 Clear Cell 3 F Liver
13 36 68 4.5 Clear Cell 1 M Bone
14 6 56 11 Clear Cell 3 F Pituitary
15 120 47 8 Clear Cell 3 M Testes
16 24 54 6.5 Clear Cell 2 F Soft Tissue
17 48 62 10.5 Clear Cell 3 M Bone
18 156 56 3.5 Clear Cell 3 M Lung
19 108 59 8.5 Clear Cell 2 M Lung
20 12 28 4 Mixed 3 M Lymph Node
21 6 54 Unknown Clear Cell 2 M Lung
22 12 40 3.7 Mixed 4 M Lung
23 6 64 3.5 Clear Cell 2 M Bone
24 84 46 14.5 Clear Cell 2 F Lung
25 36 55 8.5 Clear Cell 2 M Lung
26 36 66 6.5 Clear Cell 2 M Adrenal
27 132 72 5 Clear Cell 2 F Adrenal
28 12 72 6 Mixed 3 F Soft Tissue
29 6 52 3.5 Clear Cell 3 F Bone
30 12 50 12 Clear Cell 2 F Skin
31 6 33 3.5 Clear Cell 2 M Bone
32 36 69 10.5 Clear Cell 3 F Bone
33 12 62 6 Clear Cell 3 M Bone
34 36 47 8 Clear Cell 3 F Lung
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value of 0.002 for MEK is below the Bonferroni
adjusted p-value (0.003) for the 16 markers analyzed at
an alpha of 0.05. As MEK is an important component
of the major intracellular proliferation signaling path-
way, we looked at percentage of cells in tumors with
ki67 staining, and found that ki67 positivity was sig-
nificantly higher (P = 0.0006) in metastatic than pri-
mary tumors.Given that archival tissue is often available from either
the primary or the metastatic site, but not both, we
determined the associations between marker expression
in paired primary and metastatic samples using the
Pearson correlation test, as displayed in Table 3. Levels
correlated well between primary and metastatic
specimens for most markers, with the poorest correl-
ation seen for FGF-R1 and VEGF-D (0.15 and 0.28,
respectively).
Figure 1 Example of Automated Quantitative Analysis (AQUA) staining for CRAF in matched primary (upper panels) and metastatic
(lower panels) specimens from a single patient: We used anti-cytokeratin antibodies to create a cytoplasmic compartment (two upper
right quadrants). A tumor mask was made by filling in holes (upper left quadrants). 4’, 6-diamidino-2-phenylindole (DAPI) defines the nuclear
compartment within the tumor mask (left lower quadrants). CRAF expression is measured within the cytoplasmic compartments, within the
tumor mask (lower right quadrants), and each clinical case is assigned a score based on pixel intensity per unit area within the tumor mask. The
upper panel shows an example of a histospot from a primary specimen and the lower shows the corresponding metastatic tumor. CRAF staining
was strong and similar in both specimens.
Aziz et al. BMC Clinical Pathology 2013, 13:3 Page 5 of 9
http://www.biomedcentral.com/1472-6890/13/3To determine whether there were differences in intra-
tumor heterogeneity in primary and metastatic speci-
mens, we used the four measurements from each tumor.
Each core is represented by a vector of measurements of
all markers, denoted as the core vector. For each patient
we computed the median core vector and measured its
L1 distances from the corresponding four core vectors.
We defined the composite median absolute deviation
(MAD) as the median of these four L1 distances, and
used it as a proxy for estimating intra-tumor heterogen-
eity. For each patient, the composite MAD is computed
separately for his/her primary and metastatic tumors.
Using the Wilcoxon paired, two-sided signed rank test,
we found no significant differences in heterogeneity
between primary and metastatic tumors (P = 0.38), as
shown in Figure 2.Discussion
Molecular targeted therapies that inhibit members of
the VEGF pathway and mTOR are now widely used for
the treatment of metastatic RCC. At present, no pre-
dictive biomarkers have been established for this class
of drugs. Given that these agents inhibit this pathway
at the protein level, target protein expression might be
associated with response to therapy. Many metastatic
RCC patients have either primary or metastatic tumor
tissue (but not both) available for analysis, and our
purpose was therefore to determine differences in
expression of these drug targets in matched primary
and metastatic specimens.
Target expression levels were not globally different
between primary and metastatic tumors, with the
exception of MEK1, which was higher in metastatic
Table 2 Tyrosine kinase and mTOR inhibitor target










B-Raf 32.1 ± 8.9 31.2 ± 10.2 −0.417 0.678
C-Raf 26.7 ± 2.1 28.4 ± 2.5 0.519 0.605
cKit 23.3 ± 1.3 23.4 ± 1.3 0.079 0.937
FGF-R1 29.1 ± 1.1 29.9 ± 0.9 0.579 0.564
HIF-2α 58.2 ± 1.9 58.2 ± 2.0 0.014 0.989
mTOR 18.8 ± 1.4 22.4 ± 1.8 1.637 0.106
PDGF-Rβ 24.7 ± 0.9 27.9 ± 1.5 1.879 0.064
VEGF-R1 22.6 ± 0.9 23.9 ± 1.2 0.34 0.735
VEGF-R2 36.5 ± 2.4 33.5 ± 1.7 −1.294 0.200
VEGF-R3 45.6 ± 2.0 46.5 ± 1.6 0.371 0.712
VEGF 24.7 ± 1.0 26.0 ± 1.1 0.907 0.367
VEGF-B 11.2 ± 0.6 11.8 ± 0.9 0.486 0.628
VEGF-C 17.0 ± 1.3 14.3 ± 1.2 −1.544 0.127
VEGF-D 35.0 ± 1.2 36.8 ± 1.3 1.018 0.312
MEK1 37.5 ± 2.5 50.3 ± 3.1 3.183 0.002
ERK1/2 17.0 ± 1.1 18.6 ± 1.7 0.802 0.425
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major intracellular proliferation signal transduction
pathway, we studied ki67 expression in primary and
metastatic samples and found that the percentage of
ki67 positive cells was also significantly higher in the


















ERK 1/2 0.36clinical picture in which the primary tumor grows over
years, yet the course for metastatic disease patients is
often much shorter due to rapid metastatic tumor
growth.
Our data indicate that our ability to predict expression
in primary specimens based on measurements from a
corresponding metastasis and vice-versa is marker
dependent. The intra-patient correlations were variable
across markers, with the worst correlation shown for
VEGF-D and FGF-R1, while other makers such as
C-Raf, VEGF-R2 and cKIT demonstrated excellent
correlations between levels in primary and metastatic
specimens. These findings are consistent with the only
other similar published study of which we are aware in
which mTOR pathway members were assessed for con-
cordance between primary and metastatic sites using
standard immunohistochemistry (IHC) [26]. Levels of
phosphorylated mTOR were similar in primary and
metastatic sites, while levels of PI3K, p-Akt, PTEN and
p70S6 had much weaker intra-patient correlations. We
elected not to study levels of phosphorylated proteins in
our study, as many of these specimens were old and
fixation times were not uniform. Phosphatase activity,
therefore, cannot be accounted for in our samples. Use
of nominal IHC scores might make similarities in
expression less apparent than use of continuous AQUA
scores.
To date, none of the approved drugs for mRCC has an
associated companion diagnostic biomarker test. A
number of initial attempts have been made at develop-
ing predictive biomarkers that are primarily centered
around VHL pathway markers, such as VHL mutations,
HIF levels, VEGF isoforms and VEGF receptor levels.
Phase II trials of axitinib or temsirolimus revealed no
association between VHL mutational status and
response to therapy [10,31]. Higher levels of pS6 and
p-AKT in pre-treatment tissues were associated with
response to temsirolimus, but no significant difference
was found between primary and metastatic tissues. In
addition, a number of studies have looked at VHL loss
and response to immunotherapy [31,32]. A study of 123
patients with clear cell RCC showed that patients with
wild-type VHL had a lower likelihood of responding to
VEGF-pathway targeted therapies than patients with
VHL mutations or VHL loss by hypermethylation [33].
This finding, however, requires further validation.
Small studies have suggested a potential role for
VEGF and soluble forms of the VEGF receptors as pre-
dictors of response to VEGF pathway targeting therapies
and cytokine therapies. Sabatino et al. [34] measured
serum protein levels using multiplex protein arrays, and
showed that high pretreatment levels of VEGF and
fibronectin were negative predictors of response to IL-2.
Trials using bevacizumab with interferon or sorafenib
Figure 2 Comparison between heterogeneity within primary
and metastatic specimens, estimated using a composite
median absolute deviation (MAD) across all the markers: Each
patient is represented by a dot. Dots above the diagonal
represent patients with larger heterogeneity in the primary tumors,
while dots below the diagonal represent greater heterogeneity in
the corresponding metastatic tumors. The central diagonal grey line
represents identical heterogeneity in primary and metastatic tumors.
The Wilcoxon paired, two-sided signed rank test shows no
significant difference between the heterogeneities of the primary
and matched metastatic tumors (p = 0.38).
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in patients [13,17]. In a phase II trial, Hutson et al.
found that decreased expression of soluble VEGFR-2
correlated with tumor response to pazopanib [35]. Simi-
larly, in a phase II trial of sunitinib, increases in soluble
VEGFR-2, VEGFR-3, and VEGF at day 28 were asso-
ciated with a greater likelihood of response [36].
Clinical observations of discordance in response of
primary and metastatic tumors suggest possible differ-
ences in biology. Alternatively, differences in response
could be due to variable tumor microenvironment in
the primary and metastatic sites. Primary RCC tumors
do not seem to respond as well as RCC metastatic sites
to VEGF pathway targeted therapies [25]. Studies evalu-
ating targeted therapies in RCC for their preoperative
potential to reduce the size of primary tumors with the
hope of making them more resectable are ongoing. Prior
studies evaluating sunitinib and/or sorafenib in patients
with localized and metastatic RCC disease concluded
that these agents might be useful in reducing primary
tumor burden [21-24,37]. A phase II study of presurgi-
cal sunitinib resulted in only 1 partial primary tumor
response, while another study concluded that preopera-
tive sunitinib can be effective for cytoreduction. Eightypercent of patients demonstrated variable primary
tumor shrinkage, with a median of 1.6 cm (range 0.4-
5.1) [38,39]. A larger study of 168 mRCC patients who
received targeted therapy with their primary tumors in
situ found noted negligible decreases in the size of the
primary tumors [25]. Although contradictory, these
studies do suggest discordant responses to drugs in pri-
mary and metastatic tumors. Additional trials are
needed to determine whether any of the biomarkers
studied here is predictive of response to VEGF pathway
targeting therapies, and when discordant tumor shrink-
age is observed, whether it can be explained by dif-
ferences in biomarker expression in primary and
metastatic samples.
Biomarker studies related to evolving biomarkers and
experimental drugs are being done by our group and
others. The clinical relevance of HIF-1α and HIF-2α are
being studied as the hypoxia induced pathway is regularly
aberrant in RCC. HIF-1α has been shown to be expressed
in most RCC tumors while HIF-2α is relatively absent in
early tumors, but is highly expressed in metastatic tumors
[40,41]. B7-H1 is another target that is being heavily
explored, with multiple clinical trials of B7-H1 targeting
ongoing. A study by Thompson et. al in primary and
metastatic RCC showed high B7-H1 expression is asso-
ciated with a poor prognosis. Although only 1 patient was
represented in both cohorts, more metastatic specimens
had high B7-H1 expression than primary specimens
(54.3% versus 44.4%, respectively) [42]. Tumor suppressor
gene p53 was significantly higher in primary tumors ver-
sus metastatic tumors in a study by Zigeuner et. al (22.8%
versus 51.8%), however the specimens were not matched
[43]. In a study of mTOR and hypoxia-induced pathway
members including 135 primary RCC and 41 unrelated
metastasis, differential global patterns of expression were
measured. Levels of p-AKT, p-S6, 4EBP1, and c-myc were
higher in metastatic lesions compared to both primary
and benign tissues [44].
The tumors studied here exhibited variable intratu-
mor heterogeneity in the four tumor cores. The degree
of heterogeneity is not significantly different in primary
and metastatic samples. Although our study evaluates
protein expression, recent DNA sequencing studies
have shown intratumor heterogeneity in primary renal
cell carcinoma. The majority of somatic mutations (over
60%) were not present throughout the tumor in the 4
samples examined. Moreover, DNA signatures of both
good and poor prognosis were detected in different
regions of the same tumor. The authors suggest that
intratumor heterogeneity is the cause of lack of repro-
ducible predictive biomarkers [45]. Utilizing single-cell
exome sequencing in a single patient, Xu et al. demon-
strated that there was no dominant clone throughout
the tumor, and similarly demonstrated heterogeneity at
Aziz et al. BMC Clinical Pathology 2013, 13:3 Page 8 of 9
http://www.biomedcentral.com/1472-6890/13/3the DNA level. This may provide insight into the
observed heterogeneity in this study [46].
Conclusion
Our studies showed good concordance between primary
and metastatic samples for most of the markers studied.
The biomarkers with the least concordance were FGF-R1
and VEGF-D. The discordance in levels of VEGF-D might
be due to the fact that this is a secreted protein, and levels
of FGF-R1 might be more influenced by the tumor micro-
environment than the other markers studied. Conversely,
other biomarkers showed excellent concordance between
primary and metastatic samples. As predictive biomarkers
are developed, careful studies are needed to define con-
cordance versus discordance for individual biomarkers in
order to determine whether primary specimen measure-
ments can be used as surrogates for metastatic specimens
and vice-versa.
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